IP Library Granted Patent US 9,365,644
Granted Patent B2
US 9,365,644 · App. 12/425,763 · Granted Jun 14, 2016

Anti-TNFα antibody

Inventors: Yaohuang Ke (San Francisco, CA); Guo-Liang Yu (Berkeley, CA)
Assignee: EPITOMICS, INC.
C07K16/241C07K2317/56C07K2317/565C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,365,644
App. No.
12/425,763
Granted
Jun 14, 2016
Kind
B2
Abstract

An antibody that binds TNF α and neutralizes its activity is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO. 1, and b) a light chain variable domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID No. 2.

Claims (18)

1. An antibody, comprising:

a) a heavy chain variable domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO. 1 ; and

b) a light chain variable domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID No. 2,

wherein the antibody binds TNFα.

2. The antibody of claim 1 , wherein said antibody is a monovalent antibody.

3. The antibody of claim 1 , wherein said antibody is a bivalent antibody.

4. The antibody of claim 1 , wherein said antibody is a single chain antibody.

5. The antibody of claim 1 , wherein said antibody is a monoclonal antibody.

6. The antibody of claim 1 , wherein said antibody comprises a single antigen binding arm and an Fc region.

7. The antibody of claim 1 , wherein said antibody is humanized.

8. The antibody of claim 1 , wherein the antibody is conjugated to an agent.

9. The antibody of claim 1 , wherein said heavy chain variable domain comprises CDR regions that are identical to those shown in FIG. 1 and said light chain variable domain comprises CDR regions that are identical to those shown in FIG. 1 and wherein any changes in the amino acid sequence of said antibody relative to SEQ ID NOs: 1 and 2 occur in framework sequence.

10. The antibody of claim 1 , where said antibody comprises CDRs that are otherwise identical to the CDRs of the antibody shown in FIG. 1 except for up to four amino acid substitutions in said CDRs.

11. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

12. The antibody of claim 1 , wherein said antibody comprises

a) a heavy chain variable domain comprising an amino acid sequence that is identical to the amino acid sequence of SEQ ID NO. 1; and

b) a light chain variable domain comprising an amino acid sequence that is identical to the amino acid sequence of SEQ ID No. 2,

wherein the antibody binds TNFα.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2009
From: KE, YAOHUANG; YU, GUO-LIANG
To: EPITOMICS, INC.
Reel/Frame 022674/0306 →
Continuity (2)
Provisional Application 61047358 · Apr 23, 2008
Related Publication 20090269357A1 · Oct 29, 2009